SHP2(WT)@pLKO-Trex-SBP Citations (1)

Originally described in: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD Nature. 2016 Jul 7;535(7610):148-52. PubMed Journal

---

Articles Citing SHP2(WT)@pLKO-Trex-SBP

Articles
The YAP-Interacting Phosphatase SHP2 can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma. Buckarma EH, Werneburg NW, Conboy CB, Kabashima A, O'Brien DR, Wang C, Rizvi S, Smoot RL. Mol Cancer Res. 2020 Jul 9. pii: 1541-7786.MCR-20-0165. doi: 10.1158/1541-7786.MCR-20-0165. PubMed

If you have published an article using this material, please email us at to have your article added to this page.